Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor II-I repeat domain-containing protein 2B (GTF2IRD2B) is a glycosylated phosphoprotein with a leucine zipper motif, two helix-loop-helix (I repeat) domains, a BED zinc finger, and a C-terminal CHARLIE8 transposon-like element[1][3]. It is a member of the TFII-I family of transcription factors and appears to have a role in gene regulation through interactions with TFII-I and other family members, possibly sequestering or antagonizing their function in the nucleus[1][2]. The gene is primate-specific, with evolutionary origin following gene duplication events, and lies within a chromosomal region involved in Williams-Beuren syndrome[1][3]. Experimental data suggest it modulates transcription via direct protein-protein interactions and subnuclear localization changes, but its direct functions are not fully characterized; recent findings support its role as a regulatory fine-tuner in both species-specific development and potentially pathological processes such as in hepatocellular carcinoma[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor II-I repeat domain-containing protein 2B (GTF2IRD2B).